Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?
Immune checkpoint inhibitors (ICI) have improved the outcomes for patients with advanced cancers, also resulting in increased numbers of long-term survivors in subgroups of patients with metastatic disease or irresectable tumors. In advanced stage melanoma, for example, a pooled analysis has shown an overall survival (OS) rate of 20% at 10 years in patients treated with ipilimumab. An OS rate of 34% at 5 years was seen when given a programmed cell death protein 1 (PD-1) antibody, for treatment-na ïve patients this was 40% [1–3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Daan G. Knapen, Derk Jan A. de Groot, Thomas C. Kwee, Emmy I.M. Meijne, Rudolf S.N. Fehrmann, Elisabeth G.E. de Vries Tags: Controversy Source Type: research